Elvin H Geng1, Thomas A Odeny2, Rita Lyamuya3, Alice Nakiwogga-Muwanga4, Lameck Diero5, Mwebesa Bwana6, Paula Braitstein5, Geoffrey Somi3, Andrew Kambugu4, Elizabeth Bukusi2, Megan Wenger7, Torsten B Neilands1, David V Glidden7, Kara Wools-Kaloustian8, Constantin Yiannoutsos9, Jeffrey Martin10,7. 1. Departmentof Medicine, Division of HIV/AIDS, San Francisco General Hospital, California. 2. Kenya Medical Research Institute and the Family AIDS Care and Education Services Program, Nairobi. 3. National AIDS Control Program, Dar es Salaam, Tanzania. 4. Infectious Diseases Institute, Kampala, Uganda. 5. US Agencyfor International Development-Academic Model Providing Access to Healthcare Program, Eldoret, Kenya. 6. Mbarara University of Science and Technology, Uganda. 7. Department of Epidemiology and Biostatistics, University of California, San Francisco. 8. Division of Infectious Diseases, Department of Medicine. 9. Department of Biostatistics, Fairbanks School of Public Health, Indiana University, Indianapolis. 10. Department of Medicine, Division of HIV/AIDS, San Francisco General Hospital, California.
Abstract
BACKGROUND: Improving the implementation of the global response to human immunodeficiency virus requires understanding retention after starting antiretroviral therapy (ART), but loss to follow-up undermines assessment of the magnitude of and reasons for stopping care. METHODS: We evaluated adults starting ART over 2.5 years in 14 clinics in Uganda, Tanzania, and Kenya. We traced a random sample of patients lost to follow-up and incorporated updated information in weighted competing risks estimates of retention. Reasons for nonreturn were surveyed. RESULTS: Among 18 081 patients, 3150 (18%) were lost to follow-up and 579 (18%) were traced. Of 497 (86%) with ascertained vital status, 340 (69%) were alive and, in 278 (82%) cases, updated care status was obtained. Among all patients initiating ART, weighted estimates incorporating tracing outcomes found that 2 years after ART, 69% were in care at their original clinic, 14% transferred (4% official and 10% unofficial), 6% were alive but out of care, 6% died in care (<60 days after last visit), and 6% died out of care (≥ 60 days after last visit). Among lost patients found in care elsewhere, structural barriers (eg, transportation) were most prevalent (65%), followed by clinic-based (eg, waiting times) (33%) and psychosocial (eg, stigma) (27%). Among patients not in care elsewhere, psychosocial barriers were most prevalent (76%), followed by structural (51%) and clinic based (15%). CONCLUSIONS: Accounting for outcomes among those lost to follow-up yields a more informative assessment of retention. Structural barriers contribute most to silent transfers, whereas psychological and social barriers tend to result in longer-term care discontinuation.
BACKGROUND: Improving the implementation of the global response to human immunodeficiency virus requires understanding retention after starting antiretroviral therapy (ART), but loss to follow-up undermines assessment of the magnitude of and reasons for stopping care. METHODS: We evaluated adults starting ART over 2.5 years in 14 clinics in Uganda, Tanzania, and Kenya. We traced a random sample of patients lost to follow-up and incorporated updated information in weighted competing risks estimates of retention. Reasons for nonreturn were surveyed. RESULTS: Among 18 081 patients, 3150 (18%) were lost to follow-up and 579 (18%) were traced. Of 497 (86%) with ascertained vital status, 340 (69%) were alive and, in 278 (82%) cases, updated care status was obtained. Among all patients initiating ART, weighted estimates incorporating tracing outcomes found that 2 years after ART, 69% were in care at their original clinic, 14% transferred (4% official and 10% unofficial), 6% were alive but out of care, 6% died in care (<60 days after last visit), and 6% died out of care (≥ 60 days after last visit). Among lost patients found in care elsewhere, structural barriers (eg, transportation) were most prevalent (65%), followed by clinic-based (eg, waiting times) (33%) and psychosocial (eg, stigma) (27%). Among patients not in care elsewhere, psychosocial barriers were most prevalent (76%), followed by structural (51%) and clinic based (15%). CONCLUSIONS: Accounting for outcomes among those lost to follow-up yields a more informative assessment of retention. Structural barriers contribute most to silent transfers, whereas psychological and social barriers tend to result in longer-term care discontinuation.
Authors: Elvin H Geng; David V Glidden; David R Bangsberg; Mwebesa Bosco Bwana; Nicholas Musinguzi; Denis Nash; John Z Metcalfe; Constantin T Yiannoutsos; Jeffrey N Martin; Maya L Petersen Journal: Am J Epidemiol Date: 2012-02-03 Impact factor: 4.897
Authors: Elvin H Geng; David V Glidden; Mwebesa Bosco Bwana; Nicolas Musinguzi; Nneka Emenyonu; Winnie Muyindike; Katerina A Christopoulos; Torsten B Neilands; Constantin T Yiannoutsos; Steven G Deeks; David R Bangsberg; Jeffrey N Martin Journal: PLoS One Date: 2011-07-26 Impact factor: 3.240
Authors: Janneke H van Dijk; Catherine G Sutcliffe; Bornface Munsanje; Francis Hamangaba; Philip E Thuma; William J Moss Journal: BMC Infect Dis Date: 2009-10-16 Impact factor: 3.090
Authors: Norma C Ware; Monique A Wyatt; Elvin H Geng; Sylvia F Kaaya; Oche O Agbaji; Winnie R Muyindike; Guerino Chalamilla; Patricia A Agaba Journal: PLoS Med Date: 2013-01-08 Impact factor: 11.069
Authors: Linh Tran; Constantin T Yiannoutsos; Beverly S Musick; Kara K Wools-Kaloustian; Abraham Siika; Sylvester Kimaiyo; Mark J van der Laan; Maya Petersen Journal: Epidemiol Methods Date: 2016-11-10
Authors: Lillian B Brown; Diane V Havlir; James Ayieko; Florence Mwangwa; Asiphas Owaraganise; Dalsone Kwarisiima; Vivek Jain; Theodore Ruel; Tamara Clark; Gabriel Chamie; Elizabeth A Bukusi; Craig R Cohen; Moses R Kamya; Maya L Petersen; Edwin D Charlebois Journal: AIDS Date: 2016-11-28 Impact factor: 4.177
Authors: Hana Lee; Joseph W Hogan; Becky L Genberg; Xiaotian K Wu; Beverly S Musick; Ann Mwangi; Paula Braitstein Journal: Stat Med Date: 2017-11-22 Impact factor: 2.373
Authors: Kathrin Zürcher; Anne Mooser; Nanina Anderegg; Olga Tymejczyk; Margaret J Couvillon; Denis Nash; Matthias Egger Journal: Trop Med Int Health Date: 2017-02-20 Impact factor: 2.622
Authors: Nanina Anderegg; Leigh F Johnson; Elizabeth Zaniewski; Keri N Althoff; Eric Balestre; Matthew Law; Denis Nash; Bryan E Shepherd; Constantin T Yiannoutsos; Matthias Egger Journal: AIDS Date: 2017-04 Impact factor: 4.177
Authors: Cleophas Chimbetete; Catrina Mugglin; Tinei Shamu; Bindu Kalesan; Barbara Bertisch; Matthias Egger; Olivia Keiser Journal: Trop Med Int Health Date: 2017-06-08 Impact factor: 2.622